Severe prolonged lymphopenia as rare side-effect of dimethyl fumarate is mostly reversible. Caldito et al. report a case of persistent severe lymphopenia over 5 years after discontinuation of dimethyl fumarate. We discuss several clinical implications. Safe withdrawal of disease modifying therapies in terms of reoccurrence of disease activity and drug related adverse events need further attention as our treatment armamentarium continues to grow.
GoldRArnoldDLBar-OrA, et al. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow up of DEFINE, CONFIRM, and ENDORSE. Ther Adv Neurol Disord2020; 13: 1756286420915005.
2.
CalditoN, et al. Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation. Mult Scler J2021; 27(8): 1306–1308.
3.
ChanARoseJAlvarezE, et al. Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. Neurol Clin Pract2020; 10(6): 510–519.
NgHSKingwellEZhuF, et al. Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study. Mult Scler J2021; 27(2): 239–249.
6.
BrinerMBagnoudMMicleaA, et al. Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: Contribution of patient age. Ther Adv Neurol Disord2019; 12: 1756286419843450.
7.
LucchiniMProsperiniLBuscarinuMC, et al. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis. J Neurol. Epub ahead of print 26 January 2021. DOI: 10.1007/s00415-021-10412-0.
